FibroBiologics (FBLG) announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.” This patent strengthens FibroBiologics’ intellectual property portfolio and underscores the Company’s commitment to advancing innovative therapies for debilitating conditions like cachexia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics CEO says 2026 ‘will be about execution’
- FibroBiologics announces preclinical results for FSdC
- FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split
- FibroBiologics files IND application to initiate clinical trials of CYPS317
- FibroBiologics files to sell 22.5M shares of common stock for holders